Annovis Bio, Inc. Common Stock (ANVS)

Annovis Bio (NYSE: ANVS) announced the pricing of an underwritten public offering of 7,895,000 shares of common stock and accompanying warrants to purchase up to 7,105,500 additional shares at a combined offering price of $1.90 per share and warrant. The company expects gross proceeds of approximately $15 million before expenses, with net proceeds intended to support continued clinical development of buntanetap for Alzheimer’s and Parkinson’s disease, as well as working capital and general corporate purposes.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases, announced a proposed underwritten public offering of common stock and accompanying warrants. The company intends to use net proceeds to support continued clinical development of buntanetap in a Phase 3 Alzheimer’s disease study, as well as for working capital and general corporate purposes.

MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 7,895,000 shares of its common stock and accompanying warrants to purchase up to 7,105,500 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per share of common stock, will be exercisable immediately following the issue date and will expire six years after the date of issuance.

MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a proposed underwritten public offering in which it intends to offer and sell (i) shares of its common stock and (ii) accompanying warrants to purchase shares of common stock. The shares of common stock and the accompanying warrants will be issued separately but can only be purchased together in the proposed offering. All of the shares of common stock and the accompanying warrants will be offered by Annovis. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Annovis Bio (NYSE: ANVS) reported first-quarter 2026 business and financial results, highlighting continued advancement of its clinical-stage neurodegenerative disease programs, including 85% enrollment in its pivotal Phase 3 Alzheimer’s disease trial and closure of enrollment to new participants after reaching sufficient screening levels to meet enrollment goals.

MALVERN, Pa., May 15, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided business updates and reported financial results for the first quarter ended March 31, 2026.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13, discussing the scientific basis for treating Alzheimer’s disease as a multi-protein disorder and highlighting Annovis’ approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap, which is currently in a pivotal Phase 3 clinical trial.

MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that Maria Maccecchini, Ph.D., President and CEO, will present at Fierce Biotech Week 2026 taking place in Boston, May 12-14, 2026.

MALVERN, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a new publication titled “Buntanetap treatment in mild to moderate Alzheimer’s disease: phase 2/3 study” in a peer-reviewed journal Nature NPJ Dementia.

Let's explore the current happenings on the US markets on Monday. Below, you'll find the stocks exhibiting unusual volume in today's session.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for neurodegenerative diseases including Alzheimer’s disease and Parkinson’s disease, announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash and a recent $1.5 million investment from Board Chair Michael Hoffman, the financing is expected to extend the company’s cash runway through Q2 2027, supporting operations through a key six-month symptomatic data readout from its Phase 3 Alzheimer’s trial and the anticipated New Drug Application submission to the U.S. Food and Drug Administration, while advancing ongoing clinical studies and regulatory preparations.

MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of an underwritten public offering raising approximately $10 million in gross proceeds. Combined with existing cash on hand as well as a recent $1.5 million investment from the Board of Directors Chair, Michael Hoffman, the financing extends Annovis' cash runway through Q2 2027, fully funding the Company's operations through a key symptomatic data readout of its Phase 3 AD trial and the anticipated submission of a New Drug Application (NDA) for buntanetap to the U.S. Food and Drug Administration (FDA).

MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten offering of 5,263,156 shares of its common stock, together with accompanying warrants to purchase up to 5,263,156 shares of common stock. The combined offering price of each share of common stock and accompanying warrant is $1.90. Each warrant will be exercisable for one share of common stock at an exercise price of $2.50 per share of common stock, will be exercisable commencing six months following the issue date and will expire five years and 6 months after the date of issuance.

MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the issuance of U.S. Patent No. 12,582,632 B2, covering prevention and treatment of neurological injuries arising from brain infections through the administration of buntanetap or related compounds.

Annovis Bio (NYSE: ANVS) announced the publication of an article in The Scientist detailing the discovery and development of its lead drug candidate buntanetap, as the company advances ongoing Phase 3 and extension studies in Alzheimer’s disease and Parkinson’s disease. The company said the article provides historical and scientific context for buntanetap’s progression, with current trials showing approximately 70% enrollment in early Alzheimer’s and 20% enrollment in Parkinson’s, underscoring its focus on advancing neurodegenerative therapies toward key clinical and regulatory milestones.

MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the publication of an article in The Scientist titled “Buntanetap: From Execution Poison to Potential Alzheimer’s Disease Drug”, examining the history of discovery and development of buntanetap, the Company's lead drug candidate.

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company, announced a partnership with NeuroRPM to implement an FDA-cleared AI platform in its ongoing Parkinson’s disease study, enabling real-time monitoring of symptoms such as bradykinesia, tremor and dyskinesia through wearable and mobile technology, with the data serving as digital biomarkers to enhance disease tracking, support evaluation of buntanetap over the 36-month trial and provide deeper insights into treatment response and future clinical development.

WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital biomarker monitoring in Annovis Bio’s ANVS-25002 open-label Parkinson’s disease clinical trial. NeuroRPM’s platform uses the Apple Watch to passively collect and analyze movement data during daily activities, providing continuous measurement of key Parkinson’s motor symptoms.

MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced a partnership with NeuroRPM, a digital health technology company, to implement a new FDA-cleared artificial intelligence (AI) platform that collects movement data for symptom and disease management in its ongoing Parkinson’s study.

MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced business updates and reported financial results for the fiscal year 2025.